Alveo Wins XPRIZE Rapid Covid-19 Testing Competition. Click here to read the news.

What We Do

Alveo is leading the transformation of the consumer health tech market by developing a low-cost, easy- to-use, at-home diagnostic platform that has the potential to change the way infectious diseases are detected and managed. The company’s be.well™** testing system is designed to give individuals access to cutting-edge molecular testing and cloud-based data analytics for rapid diagnosis and management of infectious diseases. With an initial focus on acute respiratory infections including COVID-19, Flu A/B and RSV, Alveo’s agile and dynamic diagnostic platform could be adapted to detect a wide range of diseases that threaten public health. We believe affordable access to real-time, at-home results will transform the way individuals, healthcare providers and public health professionals identify and manage disease outbreaks. With be.well™, we will Know Sooner, Act Faster™ and make better-informed decisions regarding personalized intervention options that benefit individuals and the entire population*..

Who We Are

We are scientists, innovators, data-geeks, and passionate entrepreneurs. We believe that every problem has a clear solution — when you apply the right knowledge and passion. We know that protecting the health of an interconnected global society has never been more crucial. We’re up to the challenge.

We are proud to be Alveo. Meet the team that is changing the world of diagnostics.



Ron is the Founder, CEO, and Member of the Board of Directors of Alveo Technologies. Dr. Chiarello is a compassionate and successful business leader who has led a distinguished career building on more than 25 years of expertise in designing, developing and manufacturing cutting-edge micro-fluidic, micro-electronics and semiconductor technologies. An entrepreneur at heart, Dr. Chiarello has successfully founded, led, and sold multiple startups specializing in applying these technologies to a range of sensing and diagnostic challenges.

Alveo Technologies was born out of Dr. Chiarello’s vision to transform the way the medical field diagnoses, tracks, and treats infectious disease. The company’s novel diagnostic platform, be.well, has been in development since 2015. With this technology, real-time, low-cost disease detection will become broadly accessible, and could revolutionize the way we respond to, and recover from, the threat of infectious diseases like flu, RSV, COVI-19, and new threats yet to be discovered.

Prior to Alveo, Dr. Chiarello co-founded Jetalon Solutions in 2002, where he led the development and commercial deployment of Jetalon’s sensor solutions to micro-electronic, biopharmaceutical, petrochemical, and solar cell manufacturers world-wide. In 2009, Dr. Chiarello was appointed CEO of Jetalon, a position he held until 2013 when the company was acquired by Entegris. He also founded and sold Etalon Technologies (1997-2002) and Orion Metrology (2007-2010), and has provided technical advising services to many high-profile technology companies and government agencies on subjects like product development, manufacturing improvements, and environmental concerns.

Dr. Chiarello earned his Bachelor of Science in Physics at the University of California Santa Barbara and his Doctor of Philosophy (Ph.D.) in Physics from Northeastern University. Dr. Chiarello has spent more than a decade in research and development working with institutions like Argonne National Laboratory, the University of Chicago, and Stanford University, where he functioned as a program director for a number of years. Dr. Chiarello has published more than 50 technical articles, is a NATO fellow, and was the recipient of the Department of Energy Award for Excellence in Research, and the University of Chicago’s Pace Setter Award.

Ron is a career engineering, manufacturing, and supply chain executive, and currently serves Alveo Technologies as its Executive Vice President of Manufacturing and Supply Chains. He is the founder and executive director of Supply Chain Resources Group, which provides manufacturing and supply chain services in six countries to the world’s leading tech product companies and most promising start-ups, and has consulted on product operations, manufacturing, strategy, and supply chain in 22 different countries for more than 100 companies, including a dozen global Fortune 500 companies.

Ron has undergraduate degrees in both Electrical Engineering and Automated Manufacturing. He received an MA in International Management and an MBA in Operations Research from the University of Texas at Dallas where he also completed the majority of coursework towards a PhD in Organizations, Strategy, and International Management (OSIM).

Previous to Alveo Technologies, Johnson was the Head of Systems Integration & Molecular Biology at Foundation Medicine, Inc. and held senior management positions at Life Technologies and Thermo Fisher Scientific where he led systems design, integration, verification and validation for qPCR and next-generation sequencing platforms.

Johnson has led a number of molecular diagnostic product development projects from concept to commercialization at Applied MEMS, Applied Biosystems Inc., and Cepheid; designed and developed several successful microfluidics products; filed several patents; and published numerous biotechnology papers. He has extensive experience in instrument development as well as design control for 510k and PMA applications.


Ivory Chang is the Vice President of Regulatory Affairs for Alveo Technologies. Prior to joining Alveo, Ivory worked in regulatory affairs and product compliance for a number of biotech, software development, and pharmaceutical companies including CEPHEID, Genomic Health, Agilent Technology, BD Biosciences, Boston Scientific, and Roche Molecular Systems, Inc.

Ivory is RAC certified and holds a Bachelor of Science in Microbiology from Soochow University, a Postgraduate Diploma (Master) in Biomedical Engineering from the University of Surrey, and an M.S. in Advanced Instrumentation Systems from the University College London.

Rixun brings over 20 years of experience in IVD development to his role as Alveo’s Vice President of Assay Development. He has successfully led many projects from inception through development and implementation at Applied Biosystems, Life Technologies, and Thermo Fisher Scientific, following GMP/QSR/ISO compliances and the PCP process.

He has worked through IVD product 510k and PMA submissions with FDA, initiated and led collaborative projects with many internationally well-known institutions, holds six patents, and has authored multiple publications.

Doug Hart is a successful leader with 20 years in business development and marketing, Doug’s leadership has focused on driving company growth, strategic agility, relationship management and creating value for healthcare through technology.

Most recently, Doug served as the Senior Director of Business Development for Integrated Healthcare Association (IHA) where he led the business development division, managed and negotiated regional multi-million dollars in contracts. Prior to joining IHA, Doug held leadership positions with Florida Blue, Deloitte Consulting, MedeAnalytics and McKesson committed to company revenue generation and client success. His expertise is working with health plans, health systems, physician groups and government agencies. Prior his healthcare experience, he spent 11 years in sales and marketing with Sony Corporation of America.

Doug earned a Bachelors of Science in electronic engineering technology from the University of Southern Mississippi. He is a guitarist, winemaker, enjoys the outdoors and is a United States Air Force Veteran.

Prior to joining Alveo Technologies, Dmitriy was VP, Software Engineering at LumiGrow Inc, where he led development and implementation of complex multi-component IoT system for spectrum LEDs control in industrial greenhouses globally. Prior to that, Dmitriy spent 13+ years building and managing highly scalable cloud SaaS-based enterprise performance management and business analytics solutions and platforms utilizing big data, machine learning and artificial intelligence for the US and UK healthcare systems, working in companies like Manifest MedEx (California’s largest health information exchange), MedeAnalytics, Inc. and VisiQuate, Inc. where he served in a variety of senior management roles leading IT, Security administration, product engineering, development and quality assurance. His broad leadership background also includes leadership roles at Apple Inc. and Wachovia Corporation. Dmitriy holds a Bachelor of Science degree in Electrical Engineering from Ural State Technical University.
Kyle is the Engineering Director at Alveo Technologies, guiding products from early-stage R&D to manufacturing. At Alveo, Kyle has held roles of increasing responsibility including New Product Development Engineer and Engineering Manager.

Prior to his time with Alveo, Kyle worked at Entegris Jetalon as a New Product Development Engineer, serving as the team lead and taking multiple semiconductor sensor products from concept to market. Kyle received his Bachelor of Science degree from Arizona State University in Earth and Space Exploration.


Mona is the Vice President of Clinical Affairs at Alveo Technologies. Mona joins Alveo with 20 years of R&D and clinical research experience within the IVD industry. For the past 16 years, she has been strategically defining, designing, and executing clinical programs in support of successful regulatory and commercial strategies for diagnostic companies such as Abbott, Cepheid, and Roche. 

As a leader, Mona has built dynamic teams of clinical research professionals and established a network of key opinion leaders to support new product development. Her prior experiences also extend to oversight and execution of analytical V&V activities and human factors/usability testing for moderately complex and CLIA-waived tests.

Mona holds a Bachelor of Science degree in Biological Sciences and is pursuing her Master of Science degree in Regulatory Affairs.

Angie Aquino-Sales is the Senior Director, Human Resources at Alveo Technologies. Prior to joining Alveo, Angie worked at Prologis as a Senior HR Business Partner, was head of HR at OptiScan Biomedical and was the Director of HR at In these roles, she has worked with leaders on HR strategic planning and organizational design, built HR functions, and designed talent programs for leader and employee development. Angie has experience working in startups and small businesses in a variety of industries. She has also worked in large organizations at Kaiser Permanente, Blue Shield of California, and McKesson.
Angie has a Bachelor’s Degree in Industrial Psychology from California State University East Bay and a Master’s Degree in Organization Development from the University of San Francisco. She is certified in Agile HR and has SHRM-SCP certification from the Society of Human Resource Management. 
Kevin is responsible for Alveo’s Quality Management System. He brings with him over 25 years of experience working in the medical device, pharmaceutical, biotechnology, and clinical laboratory industries.

Kevin has successfully developed, implemented, and managed quality systems for a number of organizations, ranging from fledgling startups to established global corporations. He holds a bachelor’s degree in biological sciences from State University of New York at Buffalo and is an ASQ-certified Quality Auditor.

Mariana is a forward-thinking business leader and Ph.D. scientist with 18+ years of successful product development and commercialization within the In Vitro Diagnostics industry. She brings to Alveo her experience from working for mid-size medical device and reagent manufacturers and Fortune 100 companies, for example Diagnostic Products Corporation and Siemens Healthineers. Mariana has broad experience in all aspects of Immunoassay and Molecular Assay Development, US FDA and IVD regulatory submissions, approvals, and in post-acquisition Integration Management. She has a demonstrated record for excellence in R&D Operational leadership driving team’s performance and building up and leading PMO organizations with projects at a scale of up to $500M.

Mariana holds a Ph.D. in Molecular Biology from the Ruhr University in Bochum, Germany and a M.S. in Organic Chemistry from the University of Sofia, Bulgaria.

Aman is the Senior Director of Manufacturing at Alveo Technologies and is responsible for developing and implementing a sustainable manufacturing strategy for new product introductions. Aman joined Alveo from Siemens Healthineers where he was Head of New Product Introductions for the molecular diagnostics division. At Siemens, Aman was deeply involved with numerous diagnostic development projects from concept through commercialization.

Prior to Siemens, Aman worked at Chrysler LLC where he was responsible for high-volume automation scale-up and manufacturing management across multiple new vehicle launches. Aman earned his Bachelor of Science and Master of Science degrees in Mechanical Engineering from Wayne State University and Oakland University respectively.

Board of Directors











Scientific Advisory Board Members


Chief Medical Officer, Life Technologies, Inc. acquired by Thermo Fisher (2014)


Professor at Harvard & MIT, Geneticist, molecular engineer, chemist


Professor at University of Tennessee, Medical Director Le Bonheur Children’s Hospital, pediatric RSV expert


Associate Professor of Global Health, Medicine (Infectious Diseases), and Epidemiology


Chief Scientific Officer, LabCorp


Managing Director of Virgo Investments Group


President and CEO of HemaStrat LLC


Professor of Mechanical Engineering, UCSB, Director of Pennathur Laboratory for nanotechnology for bio sensing


Professor of Biomolecular Science and Mechanical Engineering, and the Associate Director of The Center for Bioengineering at UCSB



Professor of Cancer Medicine, Editor-in-Chief Oncogene


World–leading Hepatologist, practicing physician at UCLA Medical Center


Chief Medical Officer, Quest Diagnostics

1000 Atlantic Avenue, Suite 114
Alameda, CA 94501

[email protected]
[email protected]

*The be.well system is currently under development to be used by individuals over the age of 18, and for individuals over the age of 18 to perform the test on individuals under 18 years of age.
** The be.well  system is currently under development and has not received clearance, approval, or any other marketing authorization from the U.S. FDA.